Latest news
Price to earnings forward of NGM Biopharmaceuticals, Inc. – LSX:A2N7B5 - TradingViewTradingView · Thu, 06 Aug 2026 11:53:04 GMTSK Biopharmaceuticals Establishes Dedicated IP Defense Unit for Xcopri, Bracing for Generic and New Drug Competition - finance.biggo.comfinance.biggo.com · Thu, 06 Aug 2026 07:06:00 GMT1Elevan Biopharmaceuticals Is Building the Infrastructure to Be the Partner of Choice for Peptide Medicine - PR NewswirePR Newswire · Wed, 05 Aug 2026 13:30:00 GMTSK Biopharmaceuticals' Attributable Net Income Surges 158% in Q2; Shares Rise 5% - MoomooMoomoo · Wed, 05 Aug 2026 05:11:10 GMTSK Biopharmaceuticals Posts Record Q2 Operating Profit of ₩97.1 Billion on Surging US Xcopri Sales - finance.biggo.comfinance.biggo.com · Wed, 05 Aug 2026 02:27:00 GMTSK Biopharmaceuticals Posts Record Earnings on 45.6% Jump in Cenobamate U.S. Sales - Seoul Economic DailySeoul Economic Daily · Wed, 05 Aug 2026 01:37:51 GMTXcopri sales power SK Biopharmaceuticals to record Q2 profit - CHOSUNBIZ - ChosunbizChosunbiz · Wed, 05 Aug 2026 01:10:00 GMTBiopharmaceutical PAT market forecast to reach $4.32bn - European Pharmaceutical ReviewEuropean Pharmaceutical Review · Tue, 04 Aug 2026 13:38:58 GMT